Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Takes Part in Groundbreaking Genomes Project

Predictive Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments. An article discussing the company reads, “As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (‘UK100K’) in a research study focused on driving precision medicine to help conquer ovarian cancer. The UK100K initiative couples whole-genome sequencing of National Health Service (NHS) patients with cancer and other diseases to rich clinical data on drug treatments and outcomes. Helomics’ study centers around utilizing this data to continue improving the effectiveness of its artificial intelligence (AI)-based precision oncology models to drive both the individualization of therapy (right drug for the right patient) as well as the discovery of new treatments. Over the long term, Helomics intends to seek approval to use its precision oncology models as part of the NHS for ovarian cancer treatment.”

To view the full article, visit

About Predictive Oncology Inc.

Predictive Oncology operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic and biotech industries; and second, production of the FDA-approved STREAMWAY(R) System for automated, direct-to-drain medical fluid disposal. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI. Bookmark the permalink.

Comments are closed.